Northern Trust’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.95M | Buy |
374,852
+134,096
| +56% | +$794K | ﹤0.01% | 2989 |
|
|
2025
Q4 | $1.28M | Buy |
240,756
+6,396
| +3% | +$35.6K | ﹤0.01% | 3245 |
|
|
2025
Q3 | $1.02M | Sell |
234,360
-13,810
| -6% | -$44.7K | ﹤0.01% | 3399 |
|
|
2025
Q2 | $752K | Buy |
248,170
+175,995
| +244% | +$607K | ﹤0.01% | 3516 |
|
|
2025
Q1 | $307K | Buy |
72,175
+43,462
| +151% | +$194K | ﹤0.01% | 3781 |
|
|
2024
Q4 | $152K | Sell |
28,713
-263
| -0.9% | -$850 | ﹤0.01% | 4068 |
|
|
2024
Q3 | $53K | Hold |
28,976
| – | – | ﹤0.01% | 4192 |
|
|
2024
Q2 | $60.3K | Buy |
28,976
+11,385
| +65% | +$33.3K | ﹤0.01% | 4177 |
|
|
2024
Q1 | $70.5K | Sell |
17,591
-536
| -3% | -$1.73K | ﹤0.01% | 4167 |
|
|
2023
Q4 | $34K | Sell |
18,127
-2,460
| -12% | -$3.63K | ﹤0.01% | 4301 |
|
|
2023
Q3 | $34.4K | Hold |
20,587
| – | – | ﹤0.01% | 4246 |
|
|
2023
Q2 | $49.2K | Hold |
20,587
| – | – | ﹤0.01% | 4225 |
|
|
2023
Q1 | $64.4K | Buy |
20,587
+568
| +3% | +$1.88K | ﹤0.01% | 4197 |
|
|
2022
Q4 | $53.7K | Hold |
20,019
| – | – | ﹤0.01% | 4269 |
|
|
2022
Q3 | $59K | Hold |
20,019
| – | – | ﹤0.01% | 4284 |
|
|
2022
Q2 | $59K | Hold |
20,019
| – | – | ﹤0.01% | 4362 |
|
|
2022
Q1 | $102K | Sell |
20,019
-2,196
| -10% | -$11.5K | ﹤0.01% | 4335 |
|
|
2021
Q4 | $150K | Sell |
22,215
-64
| -0.3% | -$441 | ﹤0.01% | 4299 |
|
|
2021
Q3 | $154K | Hold |
22,279
| – | – | ﹤0.01% | 4269 |
|
|
2021
Q2 | $217K | Sell |
22,279
-34,397
| -61% | -$390K | ﹤0.01% | 4130 |
|
|
2021
Q1 | $892K | Sell |
56,676
-6,536
| -10% | -$121K | ﹤0.01% | 3630 |
|
|
2020
Q4 | $1.53M | Buy |
63,212
+26,318
| +71% | +$567K | ﹤0.01% | 3327 |
|
|
2020
Q3 | $621K | Buy |
36,894
+20,371
| +123% | +$472K | ﹤0.01% | 3549 |
|
|
2020
Q2 | $485K | Buy |
+16,523
| New | +$512K | ﹤0.01% | 3557 |
|
|
2020
Q1 | – | Sell |
-350
| Closed | -$6K | – | 4270 |
|
|
2019
Q4 | $6K | Sell |
350
-79
| -18% | -$907 | ﹤0.01% | 4220 |
|
|
2019
Q3 | $5K | Hold |
429
| – | – | ﹤0.01% | 4219 |
|
|
2019
Q2 | $7K | Hold |
429
| – | – | ﹤0.01% | 4227 |
|
|
2019
Q1 | $9K | Hold |
429
| – | – | ﹤0.01% | 4174 |
|
|
2018
Q4 | $39K | Sell |
429
-30
| -7% | -$2.12K | ﹤0.01% | 4091 |
|
|
2018
Q3 | $36K | Hold |
459
| – | – | ﹤0.01% | 4172 |
|
|
2018
Q2 | $45K | Buy |
459
+51
| +13% | +$4.75K | ﹤0.01% | 4134 |
|
|
2018
Q1 | $40K | Sell |
408
-5
| -1% | -$455 | ﹤0.01% | 4106 |
|
|
2017
Q4 | $32K | Buy |
413
+63
| +18% | +$5.05K | ﹤0.01% | 4117 |
|
|
2017
Q3 | $28K | Sell |
350
-2
| -0.6% | -$114 | ﹤0.01% | 4123 |
|
|
2017
Q2 | $21K | Hold |
352
| – | – | ﹤0.01% | 4180 |
|
|
2017
Q1 | $25K | Buy |
352
+14
| +4% | +$1.05K | ﹤0.01% | 4130 |
|
|
2016
Q4 | $26K | Buy |
338
+10
| +3% | +$3.16K | ﹤0.01% | 4085 |
|
|
2016
Q3 | $122K | Buy |
328
+1
| +0.3% | +$352 | ﹤0.01% | 3853 |
|
|
2016
Q2 | $105K | Sell |
327
-1,679
| -84% | -$502K | ﹤0.01% | 3880 |
|
|
2016
Q1 | $621K | Buy |
2,006
+20
| +1% | +$6.45K | ﹤0.01% | 3404 |
|
|
2015
Q4 | $1.23M | Buy |
1,986
+43
| +2% | +$25.2K | ﹤0.01% | 3247 |
|
|
2015
Q3 | $1.08M | Buy |
1,943
+1,529
| +369% | +$947K | ﹤0.01% | 3290 |
|
|
2015
Q2 | $296K | Buy |
+414
| New | +$256K | ﹤0.01% | 3697 |
|
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
Northern Trust's TARA Position: Q1 2026 in Review
Northern Trust increased its Protara Therapeutics (TARA) stake by 56% in Q1 2026, buying an estimated $794K and bringing the position to 374,852 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2989.
Northern Trust first reported a position in TARA in Q2 2015 and has held it in 43 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- Northern Trust held 374,852 shares of Protara Therapeutics worth $1.95M as of Q1 2026.
- Northern Trust bought 134,096 Protara Therapeutics shares in Q1 2026, an estimated $794K.
- Protara Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2989 holding.
- Northern Trust first reported a position in Protara Therapeutics in Q2 2015 and has held it in 43 quarters since.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.